---
title: Media Coverage and Research Articles
layout: page
description: 'Read about Evusheld in the media.'
image: assets/images/media.png
nav-menu: true
---
This page contains media coverage, research articles, preprints, medical opinion pieces, and policy documents. If we are missing items, please email them to [the maintainer](mailto:martin@eve.gd).

## Documents
These are documents issued or prepared by Evusheld for the UK, here released in the interests of transparency.

* Evusheld for the UK. 2022. ‘[Response to DHSC Shelving Plans for Evusheld in Winter 2022](/assets/downloads/2022-08-12-DHSC-Response.pdf)’. 12 August 2022.
* Evusheld for the UK. 2022. ‘[Response to NICE Scoping Consultation: Tixagevimab–cilgavimab for preventing COVID-19, ID6136](/assets/downloads/NICE-Scoping.pdf)’. 11 August 2022.
* Evusheld for the UK. 2022. ‘[Department of Health Plans to Deny Lifesaving Treatment to Vulnerable Patients](/assets/downloads/2022-08-10-Press-Release.pdf)’. 10 August 2022.
* Evusheld for the UK. 2022. ‘[UK “Outlier” in Not Protecting 500,000+ Vulnerable Patients with New Lifesaving Drug. AstraZeneca Denies Government Claims of Further Testing](/assets/downloads/2022-06-21-Press-Release.pdf)’. 21 June 2022.

## Media Coverage
These are articles in mainstream media/press releases about Evusheld in the UK, in reverse chronological order. It also includes statements from major UK charities on the drug.

* BBC News. ‘[Covid: Evusheld Antibody Protection Ruled out for Most Vulnerable](https://www.bbc.com/news/health-62516896)’, 12 August 2022, sec. Health.
* Gallagher, Paul. ‘[Thousands of Vulnerable “in Limbo” as Government Rules out Buying Covid Protection Drug](https://inews.co.uk/news/health/evusheld-covid-uk-drug-prevent-high-risk-groups-vulnerable-people-1790926)’. _inews.co.uk_, 12 August 2022.
* Taylor, Phil. ‘[Dismay as UK “drags Its Heels” on AZ’s COVID Antibody Evusheld](https://pharmaphorum.com/news/dismay-as-uk-drags-its-heels-on-azs-covid-antibody-evusheld/)’. _Pharmaphorum_, 12 August 2022.
* AstraZeneca. ‘[Update to Evusheld Recommended Dosage Regimen for Pre-Exposure Prophylaxis of COVID-19](https://www.astrazeneca.com/media-centre/statements/2022/update-to-evusheld-recommended-dosage-regimen-for-pre-exposure-prophylaxis-of-covid-19.html)’, 14 July 2022.
* Sarcoidosis UK. ‘[SarcoidosisUK Evusheld Statement](https://www.sarcoidosisuk.org/information-hub/evusheld/)’. _SarcoidosisUK_, 10 July 2022.
* Cardiomyopathy UK. ‘[A Statement on Evusheld](https://www.cardiomyopathy.org/news-blogs/latest-news/evusheld)’. _Cardiomyopathy UK_, 8 July 2021.
* Davies, Joe. ‘[Calls for UK to Stock up on Covid Drug That Slashes Illness by 80%](https://www.msn.com/en-gb/health/medical/calls-for-uk-to-stock-up-on-covid-drug-that-slashes-illness-by-80percent/ar-AAZj9Mf)’. _Daily Mail_, 7 July 2022.
* Lay, Kat. ‘[Calls Grow for Government to Order Covid Drug to Boost Protection for Vulnerable](https://www.thetimes.co.uk/article/calls-grow-for-government-to-order-covid-drug-to-boost-protection-for-vulnerable-h6x7gq229)’. _The Times_, 6 July 2022, sec. news.
* Lennard, Lee. ‘[Consultation for an Independent Clinical Consensus Statement for Protective Measures for VGP](/assets/downloads/2022-07-05-APPG.pdf)’. All-Party Parliamentary Group on Vulnerable Groups to Pandemics, 5 July 2022.
* Ennals, Ethan. ‘[Will Covid Drug Evusheld Be Offered to Brits Who Don’t Respond to Jab?](https://www.dailymail.co.uk/health/article-10976341/Will-Covid-drug-Evusheld-offered-vulnerable-Britons-dont-respond-vaccine.html)’. _Mail Online_, 2 July 2022.
* Mullard, Asher. ‘[COVID Antibody Drugs Have Saved Lives — so Why Aren’t They More Popular?](https://doi.org/10.1038/d41586-022-01735-7)’ _Nature_ 606, no. 7916 (29 June 2022): 854–56.
* Sharp, Christopher. ‘[Blood Cancer UK Says Government “Needs to Do More” amid Battle for Evusheld](https://www.express.co.uk/life-style/health/1629554/blood-cancer-uk-treatment-evusheld-covid)’. _Express.co.uk_, 26 June 2022.
* Shapiro, Lindsey. 2022. ‘[Evusheld Boosts Antibodies Against COVID-19 in Vaccinated MS Patients](https://multiplesclerosisnewstoday.com/news-posts/2022/06/10/evusheld-boosts-antibodies-against-covid-19-vaccinated-ms-patients/)’. _Multiple Sclerosis News Today_ (blog). 10 June 2022.
* ‘[Evusheld Significantly Prevented COVID-19 Disease Progression or Death in Tackle Phase III Treatment Trial](https://www.zawya.com/en/press-release/companies-news/evusheld-significantly-prevented-covid-19-disease-progression-or-death-in-tackle-phase-iii-treatment-trial-appg120c)’. 2022. _Zawya_. 10 June 2022.
* ‘[AstraZeneca’s Evusheld Prevents Disease Progression in Phase III Covid-19 Trial](https://www.clinicaltrialsarena.com/news/astrazeneca-evusheld-covid-trial-2/)’. 2022. _Clinical Trials Arena_ (blog). 9 June 2022.
* AstraZeneca. 2022. ‘[Evusheld Significantly Prevented COVID-19 Disease Progression or Death in TACKLE Phase III Treatment Trial](https://www.astrazeneca.com/media-centre/press-releases/2022/evusheld-significantly-prevented-covid-19-disease-progression-or-death-in-tackle-phase-iii-treatment-trial.html)’. 8 June 2022.
* Chudleigh, Hannah. 2022. ‘[AstraZeneca’s Evusheld Successfully Prevents Progression to Severe COVID-19](https://www.biospace.com/article/astrazeneca-s-evusheld-successfully-prevents-progression-to-severe-covid-19-/)’. _BioSpace_. 8 June 2022.
* Kahn, Rachel. 2022. ‘[Evusheld – Does It Work against Omicron?](https://bloodcancer.org.uk/news/evusheld-does-it-work-against-omicron/)’ _Blood Cancer UK_. 6 June 2022.
* Sharp, Christopher. 2022. ‘[Covid: Why the Threat of the Virus Still Haunts Those Who Are Immunosuppressed](https://www.express.co.uk/life-style/health/1615894/covid-kidney-disease-immunosuppressed-exclusive/amp)’. Express, 29 May 2022.
* AstraZeneca. 2022. ‘[Evusheld Long-Acting Antibody Combination Retains Neutralising Activity against Omicron Variants BA.4 and BA.5, According to New Study from University of Oxford](https://www.astrazeneca.com/media-centre/medical-releases/evusheld-long-acting-antibody-combination-retains-neutralising-activity-omicron-variants-ba4-ba5-according-new-study-university-oxford.html)’. 25 May 2022.
* Barnes, Oliver. 2022. ‘[UK Accused of Leaving Covid Immunocompromised “out to Dry”](https://www.ft.com/content/fe03bc3b-a381-462d-b373-87dabde0a9ab)’. _Financial Times_, 4 May 2022.
* Kollewe, Julia. 2022. ‘[AstraZeneca Boss Calls for UK to Provide New Covid-19 Medicine to the Vulnerable](https://www.theguardian.com/business/2022/apr/29/evusheld-covid-19-medicine-astrazeneca-immunosuppressed-vulnerable-uk)’. _The Guardian_, 29 April 2022, sec. Business.
* Ennals, Ethan. 2022. ‘[Covid 19: Vulnerable Patients Denied £800 Anti-Viral Jab Unless They Go Private](https://www.dailymail.co.uk/health/article-10746187/Covid-19-Vulnerable-patients-denied-800-anti-viral-jab-unless-private.html)’. Daily Mail. 23 April 2022.
* AstraZeneca. 2022. ‘[Evusheld Long-Acting Antibody Combination Retains Neutralising Activity against Omicron Variants Including BA.2 in New Independent Studies](https://www.astrazeneca.com/media-centre/medical-releases/evusheld-long-acting-antibody-combination-retains-neutralising-activity-against-omicron-variants-including-ba2-in-new-independent-studies.html)’. 21 March 2022.
* ‘[Evusheld Approved to Prevent COVID-19 in People Whose Immune Response Is Poor](https://www.gov.uk/government/news/evusheld-approved-to-prevent-covid-19-in-people-whose-immune-response-is-poor)’. 2022. GOV.UK. 17 March 2022.
* AstraZeneca. 2022. ‘[AstraZeneca’s Antibody Combination, Evusheld (Tixagevimab Co-Packaged with Cilgavimab) Authorised for Use in Great Britain for Pre-Exposure Prophylaxis (Prevention) of COVID-19](https://www.astrazeneca.com/media-centre/press-releases/2022/astrazenecas-antibody-combination-evusheld-authorised-for-use-in-great-britain-for-pre-exposure-prophylaxis-prevention-of-covid-19.html)’. 17 March 2022.
* ‘[Individuals with Immunodeficiency at High Risk of Mortality Following SARS-CoV-2 Infection](https://www.birmingham.ac.uk/news/latest/2022/01/covid-immunodeficiency-death-risk-infection.aspx)’. 2022. University of Birmingham. 31 January 2022.


## Research Articles, Preprints, Medical Opinion Pieces, and Policy Documents
These are formal research studies into the efficacy and dosage of Evusheld. These are arranged by alphabetical order of first author. We list here all articles (attempting a comprehensive literature review) rather than merely those with positive findings.

Articles marked [PREPRINT] have not necessarily been subject to [peer review](https://en.wikipedia.org/wiki/Peer_review).

* ‘[COVID-19 Update: Hypersensitivity Reactions with Tixagevimab/Cilgavimab (Evusheld)](https://secure.medicalletter.org/TML-article-1654d)’. The Medical Letter on Drugs and Therapeutics 64, no. 1654 (11 July 2022): 112.
* ‘[COVID-19 Update: Dosing Interval for Tixagevimab/Cilgavimab (Evusheld)](https://secure.medicalletter.org/TML-article-1656b)’. _The Medical Letter on Drugs and Therapeutics_, 8 August 2022.
* ACTIV-3–Therapeutics for Inpatients with COVID-19 (TICO) Study Group. ‘[Tixagevimab–Cilgavimab for Treatment of Patients Hospitalised with COVID-19: A Randomised, Double-Blind, Phase 3 Trial](https://doi.org/10.1016/S2213-2600(22)00215-6)’. _The Lancet Respiratory Medicine_, 8 July 2022.
* Anmar, Al-Taie. ‘[Tixagevimab and Cilgavimab: Can We See More Recommendations for Monoclonal Antibodies Beyond COVID-19 Vaccination](https://doi.org/10.1017/dmp.2022.150)’. _Disaster Medicine and Public Health Preparedness_, 8 June 2022, 1–2.
* Atluri, Kavya, Iris Aimlin, and Shitij Arora. ‘[Current Effective Therapeutics in Management of COVID-19](https://doi.org/10.3390/jcm11133838)’. Journal of Clinical Medicine 11, no. 13 (1 July 2022): 3838.
* Benotmane, Ilies, Aurélie Velay, Gabriela Gautier Vargas, Jérôme Olagne, Olivier Thaunat, Samira Fafi-Kremer, and Sophie Caillard. ‘[Pre-Exposure Prophylaxis with 300 Mg Evusheld Elicits Limited Neutralizing Activity against the Omicron Variant](https://doi.org/10.1016/j.kint.2022.05.008)’. _Kidney International_, 24 May 2022, S0085-2538(22)00383-0.
* Benotmane, Ilies, Aurélie Velay, Gabriela Gautier Vargas, Jérôme Olagne, Augustin Obrecht, Noëlle Cognard, Francoise Heibel, et al. ‘[Breakthrough COVID-19 Cases despite Prophylaxis with 150 Mg of Tixagevimab and 150 Mg of Cilgavimab in Kidney Transplant Recipients](https://doi.org/10.1111/ajt.17121)’. _American Journal of Transplantation_. Accessed 23 June 2022.
* Boschi, Céline, Philippe Colson, Audrey Bancod, Valérie Moal, and Bernard La Scola. ‘[Omicron Variant Escapes Therapeutic Monoclonal Antibodies (MAbs) Including Recently Released Evusheld®, Contrary to 8 Prior Main Variant of Concern (VOC)](https://doi.org/10.1093/cid/ciac143)’. _Clinical Infectious Diseases_, 16 February 2022, ciac143.
* Bruel, Timothée, Jérôme Hadjadj, Piet Maes, Delphine Planas, Aymeric Seve, Isabelle Staropoli, Florence Guivel-Benhassine, et al. ‘[Serum Neutralization of SARS-CoV-2 Omicron Sublineages BA.1 and BA.2 in Patients Receiving Monoclonal Antibodies](https://doi.org/10.1038/s41591-022-01792-5)’. _Nature Medicine_ 28, no. 6 (June 2022): 1297–1302.
* Case, James Brett, Samantha Mackin, John M. Errico, Zhenlu Chong, Emily A. Madden, Bradley Whitener, Barbara Guarino, et al. ‘[Resilience of S309 and AZD7442 Monoclonal Antibody Treatments against Infection by SARS-CoV-2 Omicron Lineage Strains](https://doi.org/10.1038/s41467-022-31615-7)’. Nature Communications 13, no. 1 (2 July 2022): 3824.
* Chavda, Vivek P., Riddhi Prajapati, Disha Lathigara, Bhumi Nagar, Jay Kukadiya, Elrashdy M. Redwan, Vladimir N. Uversky, Mukesh N. Kher, and Rajvi Patel. ‘[Therapeutic Monoclonal Antibodies for COVID-19 Management: An Update](https://doi.org/10.1080/14712598.2022.2078160)’. _Expert Opinion on Biological Therapy_ 22, no. 6 (June 2022): 763–80.
* Conte, William L., and Lilian Golzarri-Arroyo. 2022. ‘[Tixagevimab and Cilgavimab (Evusheld) Boosts Antibody Levels to SARS-CoV-2 in Patients with Multiple Sclerosis on b-Cell Depleters](https://doi.org/10.1016/j.msard.2022.103905)’. _Multiple Sclerosis and Related Disorders_ 63 (July): 103905.
* Das, Nabarun Chandra, Pritha Chakraborty, Jagadeesh Bayry, and Suprabhat Mukherjee. ‘[In Silico Analyses on the Comparative Potential of Therapeutic Human Monoclonal Antibodies Against Newly Emerged SARS-CoV-2 Variants Bearing Mutant Spike Protein](https://doi.org/10.3389/fimmu.2021.782506)’. _Frontiers in Immunology_ 12 (2021): 782506.
* Dong, Jinhui, Seth J. Zost, Allison J. Greaney, Tyler N. Starr, Adam S. Dingens, Elaine C. Chen, Rita E. Chen, et al. ‘[Genetic and Structural Basis for SARS-CoV-2 Variant Neutralization by a Two-Antibody Cocktail](https://doi.org/10.1038/s41564-021-00972-2)’. _Nature Microbiology_ 6, no. 10 (October 2021): 1233–44.
* Fitzsimmons, William E. ‘[COVID-19 Vaccine Associated Transverse Myelitis-Evusheld as an Option When Vaccination Is Not Recommended Due to Severe Adverse Events](https://doi.org/10.1080/21645515.2022.2068338)’. Human Vaccines & Immunotherapeutics, 5 May 2022, 1–2.
* Hu, Ye-Fan, Jing-Chu Hu, Hin Chu, Thomas Yau, Bao-Zhong Zhang, and Jian-Dong Huang. ‘[In-Silico Analysis of Monoclonal Antibodies against SARS-CoV-2 Omicron](https://doi.org/10.3390/v14020390)’. _Viruses_ 14, no. 2 (14 February 2022): 390.
* [PREPRINT] Jurdi, Ayman Al, Leela Morena, Mariesa Cote, Emily Bethea, Jamil Azzi, and Leonardo V. Riella. 2022. ‘[Tixagevimab/Cilgavimab Pre-Exposure Prophylaxis Is Associated with Lower Breakthrough Infection Risk in Vaccinated Solid Organ Transplant Recipients during the Omicron Wave](https://doi.org/10.1101/2022.05.17.22274980)’. _medRxiv_.
* Kaminski, Hannah, Mickael Gigan, Agathe Vermorel, Manon Charrier, Laura Guirle, Frederic Jambon, Arthur Lacapère, et al. ‘[Covid-19 Morbidity Decreases with Tixagevimab/Cilgavimab Preexposure Prophylaxis in Kidney Transplant Recipients Non/Low Vaccine Responders](https://doi.org/10.1016/j.kint.2022.07.008)’. _Kidney International_, 20 July 2022, S0085-2538(22)00550-6.
* [PREPRINT] Karaba, Andrew H., Jake D. Kim, Teresa P.-Y. Chiang, Jennifer L. Alejo, Aura T. Abedon, Jonathan Mitchell, Amy Chang, et al. ‘[Omicron BA.1 and BA.2 Neutralizing Activity Following Pre-Exposure Prophylaxis with Tixagevimab plus Cilgavimab in Vaccinated Solid Organ Transplant Recipients](https://doi.org/10.1101/2022.05.24.22275467)’. _MedRxiv: The Preprint Server for Health Sciences_, 26 May 2022, 2022.05.24.22275467.
* Keam, Susan J. ‘[Tixagevimab + Cilgavimab: First Approval](https://doi.org/10.1007/s40265-022-01731-1)’. _Drugs_, 21 June 2022.
* Kertes, Jennifer, Shirley Shapiro Ben David, Noya Engel-Zohar, Keren Rosen, Beatriz Hemo, Avner Kantor, Limor Adler, Naama Shamir Stein, Miri Mizrahi Reuveni, and Arnon Shahar. ‘[Association between AZD7442 (Tixagevimab-Cilgavimab) Administration and SARS-CoV-2 Infection, Hospitalization and Mortality](https://doi.org/10.1093/cid/ciac625)’. _Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America_, 29 July 2022, ciac625.
* Kotton, Camille N. ‘[Belt and Suspenders: Vaccines and Tixagevimab/Cilgavimab for Prevention of COVID-19 in Immunocompromised Patients](https://doi.org/10.7326/M22-1026)’. _Annals of Internal Medicine_, 12 April 2022.
* Levin, Myron J., Andrew Ustianowski, Stéphane De Wit, Odile Launay, Miles Avila, Alison Templeton, Yuan Yuan, et al. ‘[Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19](https://doi.org/10.1056/NEJMoa2116620)’. The _New England Journal of Medicine_ 386, no. 23 (9 June 2022): 2188–2200.
* Loo, Yueh-Ming, Patrick M. McTamney, Rosalinda H. Arends, Michael E. Abram, Anastasia A. Aksyuk, Seme Diallo, Daniel J. Flores, et al. ‘[The SARS-CoV-2 Monoclonal Antibody Combination, AZD7442, Is Protective in Nonhuman Primates and Has an Extended Half-Life in Humans](https://doi.org/10.1126/scitranslmed.abl8124)’. _Science Translational Medicine_ 14, no. 635 (9 March 2022): eabl8124.
* Mahase, Elisabeth. ‘[Covid-19: AstraZeneca Says Its Antibody Drug AZD7442 Is Effective for Preventing and Reducing Severe Illness](https://doi.org/10.1136/bmj.n2860)’. _BMJ (Clinical Research Ed.)_ 375 (19 November 2021): n2860.
* NHS England RAPID-C19. 2022. ‘[Defining the Highest-Risk Clinical Subgroups upon Community Infection with SARS-CoV-2 When Considering the Use of Neutralising Monoclonal Antibodies (NMABs) and Antiviral Drugs: Independent Advisory Group Report](https://www.gov.uk/government/publications/higher-risk-patients-eligible-for-covid-19-treatments-independent-advisory-group-report/defining-the-highest-risk-clinical-subgroups-upon-community-infection-with-sars-cov-2-when-considering-the-use-of-neutralising-monoclonal-antibodies)’. _GOV.UK_. 30 May 2022.
* Nguyen, Yann, Adrien Flahault, Nathalie Chavarot, Cléa Melenotte, Morgane Cheminant, Paul Deschamps, Nicolas Carlier, et al. ‘[Pre-Exposure Prophylaxis with Tixagevimab and Cilgavimab (Evusheld©) for COVID-19 among 1112 Severely Immunocompromised Patients](https://doi.org/10.1016/j.cmi.2022.07.015)’. _Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases_, 1 August 2022, S1198-743X(22)00383-4.
* Pawankar, Ruby, Bernard Yu-Hor Thong, Marysia Tiongco-Recto, Jiu-Yao Wang, Amir Hamzah Abdul Latiff, Ting Fan Leung, Philip Hei Li, et al. ‘[Asia Pacific Perspectives on the Second Year of the COVID-19 Pandemic: A Follow-up Survey](https://doi.org/10.1111/cea.14191)’. _Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology_ 52, no. 8 (August 2022): 965–73.
* Shaikh, Suhail A., Faiza Morado, Pnada Kawewat-Ho, Rachel Cartus, Roland Davoudi, Kevin Forrester, Krist Azizian, Emily Blodget, Thin Thin Maw, and Neha Nanda. ‘[Tixagevimab-Cilgavimab: Utilization in the Solid Organ Transplant Population](https://doi.org/10.1111/ctr.14661)’. _Clinical Transplantation_ 36, no. 6 (June 2022): e14661.
* Shields, Adrian M, Ariharan Anantharachagan, Gururaj Arumugakani, Kenneth Baker, Sameer Bahal, Helen Baxendale, William Bermingham, et al. 2022. ‘[Outcomes Following SARS-CoV-2 Infection in Patients with Primary and Secondary Immunodeficiency in the UK](https://doi.org/10.1093/cei/uxac008)’. _Clinical and Experimental Immunology_, January, uxac008.
* Singson, Jason Robert C., Pam Daily Kirley, Huong Pham, Gretchen Rothrock, Isaac Armistead, James Meek, Evan J. Anderson, et al. ‘[Factors Associated with Severe Outcomes Among Immunocompromised Adults Hospitalized for COVID-19 - COVID-NET, 10 States, March 2020-February 2022](https://doi.org/10.15585/mmwr.mm7127a3)’. MMWR. Morbidity and Mortality Weekly Report 71, no. 27 (8 July 2022): 878–84.
* Stuver, Robert, Gunjan L. Shah, Neha S. Korde, Lindsey E. Roeker, Anthony R. Mato, Connie L. Batlevi, David J. Chung, et al. 2022. ‘[Activity of AZD7442 (Tixagevimab-Cilgavimab) against Omicron SARS-CoV-2 in Patients with Hematologic Malignancies](https://doi.org/10.1016/j.ccell.2022.05.007)’. _Cancer Cell_, May.
* Montgomery, Hugh, F. D. Richard Hobbs, Francisco Padilla, Douglas Arbetter, Alison Templeton, Seth Seegobin, Kenneth Kim, et al. 2022. ‘[Efficacy and Safety of Intramuscular Administration of Tixagevimab–Cilgavimab for Early Outpatient Treatment of COVID-19 (TACKLE): A Phase 3, Randomised, Double-Blind, Placebo-Controlled Trial](https://doi.org/10.1016/S2213-2600(22)00180-1)’. _The Lancet Respiratory Medicine_.
* Tada, Takuya, Hao Zhou, Belinda M. Dcosta, Marie I. Samanovic, Vidya Chivukula, Ramin S. Herati, Stevan R. Hubbard, Mark J. Mulligan, and Nathaniel R. Landau. ‘[Increased Resistance of SARS-CoV-2 Omicron Variant to Neutralization by Vaccine-Elicited and Therapeutic Antibodies](https://doi.org/10.1016/j.ebiom.2022.103944)’. _EBioMedicine_ 78 (April 2022): 103944.
* Takashita, Emi, Seiya Yamayoshi, Viviana Simon, Harm van Bakel, Emilia M. Sordillo, Andrew Pekosz, Shuetsu Fukushi, et al. ‘[Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants](https://doi.org/10.1056/NEJMc2207519)’. _New England Journal of Medicine_, 20 July 2022.
* Touret, Franck, Cécile Baronti, Hawa Sophia Bouzidi, and Xavier de Lamballerie. ‘[In Vitro Evaluation of Therapeutic Antibodies against a SARS-CoV-2 Omicron B.1.1.529 Isolate](https://doi.org/10.1038/s41598-022-08559-5)’. _Scientific Reports_ 12, no. 1 (18 March 2022): 4683.
* [PREPRINT] Tuekprakhon, Aekkachai, Jiandong Huo, Rungtiwa Nutalai, Aiste Dijokaite-Guraliuc, Daming Zhou, Helen M. Ginn, Muneeswaran Selvaraj, et al. 2022. ‘[Further Antibody Escape by Omicron BA.4 and BA.5 from Vaccine and BA.1 Serum](https://doi.org/10.1101/2022.05.21.492554)’. _bioRxiv_.
* Willicombe, Michelle, Miranda Scanlon, Fiona Loud, and Liz Lightstone. 2022. ‘[Should We Be Clinically Assessing Antibody Responses to Covid Vaccines in Immunocompromised People?](https://doi.org/10.1136/bmj.o966)’ BMJ 377 (April): o966.
* Wise, Jacqui. ‘[Covid-19: Evusheld Is Approved in UK for Prophylaxis in Immunocompromised People](https://doi.org/10.1136/bmj.o722)’. _BMJ (Clinical Research Ed.)_ 376 (17 March 2022): o722.
* [PREPRINT] Yamasoba, Daichi, Izumi Kimura, Yusuke Kosugi, Keiya Uriu, Shigeru Fujita, Jumpei Ito, Kei Sato, and The Genotype to Phenotype Japan (G2P-Japan) Consortium. ‘[Neutralization Sensitivity of Omicron BA.2.75 to Therapeutic Monoclonal Antibodies](https://doi.org/10.1101/2022.07.14.500041)’. _bioRxiv_, 15 July 2022.
* Yamasoba, Daichi, Yusuke Kosugi, Izumi Kimura, Shigeru Fujita, Keiya Uriu, Jumpei Ito, and Kei Sato. 2022. ‘[Neutralisation Sensitivity of SARS-CoV-2 Omicron Subvariants to Therapeutic Monoclonal Antibodies](https://doi.org/10.1016/S1473-3099(22)00365-6)’. _The Lancet Infectious Diseases_.
* [PREPRINT] Young-Xu, Yinong, Lauren Epstein, Vincent C. Marconi, Victoria Davey, Gabrielle Zwain, Jeremy Smith, Caroline Korves, Fran Cunningham, Robert Bonomo, and Adit A. Ginde. 2022. ‘[Tixagevimab/Cilgavimab for Prevention of COVID-19 during the Omicron Surge: Retrospective Analysis of National VA Electronic Data](https://doi.org/10.1101/2022.05.28.22275716)’. _medRxiv_.

## Secondary References
This secondary bibliography presents a selection of references on topics not directly related to Evusheld but that are of interest (e.g. the mental health implications of shielding).

* Daniels, Jo, and Hannah Rettie. ‘[The Mental Health Impact of the COVID-19 Pandemic Second Wave on Shielders and Their Family Members](https://doi.org/10.3390/ijerph19127333)’. International Journal of Environmental Research and Public Health 19, no. 12 (January 2022): 7333.

## Events
* AstraZeneca. 2022. ‘[The Unmet Needs of Immunocompromised Patients Post-COVID 19](https://www.politico.eu/event/the-unmet-needs-of-immunocompromised-patients-post-covid-19/)’. _POLITICO_. 9 June 2022.

## Media

<iframe src="https://player.vimeo.com/video/719537557?h=78adcb4cb9" width="640" height="480" frameborder="0" allow="autoplay; fullscreen; picture-in-picture" allowfullscreen></iframe>
<p><a href="https://vimeo.com/719537557">BBC News - 3pm - 21 February 2022</a> from <a href="https://vimeo.com/shannonleebanks">Shannon Banks</a> on <a href="https://vimeo.com">Vimeo</a>.</p>

<iframe width="560" height="315" src="https://www.youtube.com/embed/Xstee16fIPE" title="YouTube video player" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture" allowfullscreen></iframe>

<iframe src="https://player.vimeo.com/video/733719996?h=0be83c25e6" width="640" height="480" frameborder="0" allow="autoplay; fullscreen; picture-in-picture" allowfullscreen></iframe>
<p><a href="https://vimeo.com/733719996">Channel 5 News - 5pm - 12 July 2022</a> from <a href="https://vimeo.com/shannonleebanks">Shannon Banks</a> on <a href="https://vimeo.com">Vimeo</a>.</p>

<iframe src="https://player.vimeo.com/video/733719643?h=2563d6c38b" width="640" height="480" frameborder="0" allow="autoplay; fullscreen; picture-in-picture" allowfullscreen></iframe>
<p><a href="https://vimeo.com/733719643">ITV News - 6:30pm - 26 July</a> from <a href="https://vimeo.com/shannonleebanks">Shannon Banks</a> on <a href="https://vimeo.com">Vimeo</a>.</p>